Cargando…

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab

BACKGROUND: With no approved long-term prophylaxis (LTP) for the prevention of hereditary angioedema (HAE) attacks in Hong Kong, patients rely on compassionate use programs and drug trials. Moreover, studies regarding the use and efficacy of LTP in Asia are lacking. OBJECTIVES: Our aim was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Jane C.Y., Chiang, Valerie, Lam, Dorothy L.Y., Lee, Elaine, Lam, Ki, Au, Elaine Y.L., Li, Philip H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679768/ https://www.ncbi.nlm.nih.gov/pubmed/38024849 http://dx.doi.org/10.1016/j.jacig.2023.100166

Ejemplares similares

Lanadelumab for hereditary angioedema
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Screening for type II hereditary angioedema—the “poor man’s c1-inhibitor function”
por: Jindal, Ankur Kumar, et al.
Publicado: (2023)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Informed decision‐making in hereditary angioedema prophylaxis
por: Burnette, Autumn Ford
Publicado: (2021)

Long-term prophylaxis of hereditary angioedema with danazol
por: Xu, Yingyang, et al.
Publicado: (2022)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

Identification and Mapping of a 2,009-bp DNA Deletion in SERPING1 of a Hereditary Angioedema Patient
por: Wong, Wai-Yu, et al.
Publicado: (2019)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021)

Epidemiology, outcomes, and disproportionate burden of food-dependent exercise-induced anaphylaxis from the Hong Kong Multidisciplinary Anaphylaxis Management Initiative (HK-MAMI)
por: Chiang, Valerie, et al.
Publicado: (2023)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19
por: Papi, Alberto, et al.
Publicado: (2023)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
por: Anderson, John, et al.
Publicado: (2022)

Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
por: Soteres, Daniel F., et al.
Publicado: (2021)

Hereditary Angioedema Consensus 2010
por: Bowen, Tom
Publicado: (2010)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_64mcnemtvclai2tvgg28qgklkk